Uptake and transport of furanodiene in Caco-2 cell monolayers: A comparison study between furanodiene and furanodiene loaded PLGA nanoparticles

Chinese Journal of Natural Medicines

Volumn 11, Issue 1, 2013, Pages 49-55

  Li, Gang ^a   Lin, Dong Hai ^a   Xie, Xin Xin ^a   Qin, Li Fang ^a   Wang, Jun Teng ^a   Liu, Ke ^a  

^a YANTAI UNIVERSITY   (China)

Author keywords

Caco 2 cell monolayers; Furanodiene; Transport; Uptake

Indexed keywords

ANTIINFLAMMATORY AGENT; FURANODIENE; NANOPARTICLE; SESQUITERPENE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROPHILICITY; INTESTINE FLUID; MONOLAYER CULTURE; ZETA POTENTIAL;

EID: 84872417546     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(13)60007-2     Document Type: Article

References (28)

1. Dolara P, Luceri C, Ghelardini C, et al. Analgesic effects of myrrh [J]. Nature 1996, 379(6560):29.
2. Lai EY, Chyau CC, Mau JL, et al. Antimicrobial activity and cytotoxicity of the essential oil of Curcuma zedoaria [J]. Am J Chin Med 2004, 32(2):281-290.
3. Sun XY, Zheng YP, Lin DH, et al. Potential anti-cancer activities of furanodiene, a sesquiterpene from Curcuma wenyujin [J]. Am J Chin Med 2009, 37(3):589-596.
4. Yang FQ, Li SP, Zhao J, et al. Optimization of GC-MS conditions based on resolution and stability of analytes for simultaneous determination of nine sesquiterpenoids in three species of Curcuma rhizomes [J]. J Pharm Biomed Anal 2007, 43(1):73-82.
5. Leng W, Zheng Y, Li SP, et al. Study on absorption mechanisms of zedoary turmeric oil by Caco-2 cell model [J]. Chin Pharm J 2007, 42(16):1228-1232.
6. Hans ML, Lowman AM Biodegradable nanoparticles for drug delivery and targeting [J]. Curr Opin Solid State Mater Sci 2002, 6(4):319-327.
7. Jain RA The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices [J]. Biomaterials 2000, 21(23):2475-2490.
8. Panyam J, Labhasetwar V Biodegradable nanoparticles for drug and gene delivery to cells and tissue [J]. Adv Drug Deliv Rev 2003, 55(3):329-347.
9. Romberg SB, Hennink WE, Storm G Sheddable coatings for long-circulating nanoparticles [J]. Pharm Res 2008, 25(1):55-71.
10. Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles [J]. Mol Pharm 2008, 5(4):505-515.
11. Gref R, Minamitake Y, Peracchia MT Biodegradable long-circulating polymeric nanospheres [J]. Science 1994, 263(18):1600-1603.
12. Tang BC, Dawson M, Laia SK Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier [J]. Proc Natl Acad Sci USA 2009, 106(46):19268-19273.
13. Cu Y, Booth CJ, Saltzman WM In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery [J]. J Control Release 2011, 156(2):258-264.
14. des Rieux A, Fievez V, Momtaz M Helodermin-loaded nanoparticles: characterization and transport across an in vitro model of the follicle-associated epithelium [J]. J Controlled Release 2007, 118(3):294-302.
15. Garinot M, Fiévez V, Pourcelle V, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination [J]. J Controlled Release 2007, 120(3):195-204.
16. Tobío M, Sánchez A, Vila A, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration [J]. Colloids Surf B Biointerfaces 2000, 18(3-4):315-323.
17. Nguyen CA, Allemann E, Schwach G, et al. Cell interaction studies of PLA-MePEG nanoparticles [J]. Int J Pharm 2003, 254(1):69-72.
18. Park J, Fong PM, Lu J, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin [J]. Nanomedicine 2009, 5(4):410-418.
19. Danhier F, Lecouturier N, Vroman B, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation [J]. J Control Release 2009, 133(1):11-17.
20. Murakami H, Kobayashi M, Takeuchi H, et al. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles [J]. Powder Technol 2000, 107(3):137-143.
21. Sorensen EN, Weisman G, Vidaver GA A Sephadex column procedure for measuring uptake and loss of low molecular weight solutes from small, lipid-rich vesicles [J]. Anal Biochem 1977, 82(2):376-384.
22. Pharmacopoeia of the People's Republic of China[S]. Beijing, China, Appendix A.85. 2010.
23. Couvreur P, Puisieux F Nano- and microparticles for the delivery of polypeptides and proteins [J]. Adv Drug Deliv Rev 1993, 10(2-3):141-162.
24. Win KY, Feng SS Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs [J]. Biomaterials 2005, 26(15):2713-2722.
25. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres [J]. Adv Drug Deliv Rev 1995, 16(2):215-233.
26. Vila A, Sánchez A, Tobío M, et al. Design of biodegradable particles for protein delivery [J]. J Controlled Release 2002, 78(1-3):15-24.
27. Chen J, Li S, Shen Q, et al. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer [J]. Drug Dev Ind Pharm 2011, 37(11):1339-1346.
28. Pamujula S, Hazari S, Bolden G, et al. Cellular delivery of PEGylated PLGA nanoparticles [J]. J Pharm Pharmacol 2012, 64(1):61-67.